Literature DB >> 2900934

Tamoxifen as risk factor for carcinoma of corpus uteri.

L Hardell.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 2900934     DOI： 10.1016/s0140-6736(88)92675-x

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  17 in total

1.  Suppression of Estrogenic Activity by Medroxyprogesterone Acetate in Tamoxifen-treated Patients after Surgery for Breast Cancer to Reduce the Risk of Endometrial Cancer Development.

Authors: 
Journal:  Breast Cancer       Date:  1996-03-29       Impact factor: 4.239

Review 2.  Long-term adjuvant tamoxifen therapy for breast cancer.

Authors:  V C Jordan
Journal:  Breast Cancer Res Treat       Date:  1990-05       Impact factor: 4.872

3.  Proven value of translational research with appropriate animal models to advance breast cancer treatment and save lives: the tamoxifen tale.

Authors:  V Craig Jordan
Journal:  Br J Clin Pharmacol       Date:  2015-02       Impact factor: 4.335

Review 4.  Tamoxifen in breast cancer ipse dixit in uterine malignant mixed Müllerian tumor and sarcoma-A report of 8 cases and review of the literature.

Authors:  Ana Luisa Cardoso Vasconcelos; Beatriz Nunes; Catarina Duarte; Vera Mendonça; Joana Ribeiro; Marília Jorge; Isabel Monteiro Grillo
Journal:  Rep Pract Oncol Radiother       Date:  2013-08-12

Review 5.  The molecular, cellular and clinical consequences of targeting the estrogen receptor following estrogen deprivation therapy.

Authors:  Ping Fan; Philipp Y Maximov; Ramona F Curpan; Balkees Abderrahman; V Craig Jordan
Journal:  Mol Cell Endocrinol       Date:  2015-06-05       Impact factor: 4.102

Review 6.  Gynecologic effects of tamoxifen: case reports and review of the literature.

Authors:  R M Caputo; L J Copeland
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  1996

7.  The effect of tamoxifen on the endometrium.

Authors:  B Uziely; A Lewin; G Brufman; D Dorembus; S Mor-Yosef
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

8.  Tamoxifen stimulates in vivo growth of drug-resistant estrogen receptor-negative breast cancer.

Authors:  J Maenpaa; V Wiebe; S Koester; G Wurz; V Emshoff; R Seymour; P Sipila; M DeGregorio
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

Review 9.  Gynaecologic effects of tamoxifen.

Authors:  D Y Kuo; C D Runowicz
Journal:  Med Oncol       Date:  1995-06       Impact factor: 3.064

Review 10.  What do we know and what don't we know about tamoxifen in the human uterus.

Authors:  A Friedl; V C Jordan
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.